Amyris Hosts Successful First Session Of Its Virtual Investor Mini-Series

Rhea-AI Summary

Amyris, a synthetic biotechnology firm listed on Nasdaq as AMRS, successfully hosted the first session of its virtual investor mini-series, titled "Delivering on the Promise of Synthetic Biology." This session, held on December 15, 2020, featured nearly 300 participants and included a business update, technology presentation, and Q&A. CEO John Melo discussed strategic transactions and future outlook, while SVP Sunil Chandran showcased the company's technology platform. Future sessions are planned, focusing on the Consumer and Ingredients portfolios in Q1 2021.

Positive

• Well-attended virtual investor mini-series with nearly 300 participants.
• CEO provided insight into strategic transactions and company portfolio.
• Demonstrated advanced technology capabilities in the presentation.

Negative

• None.

EMERYVILLE, Calif., Dec. 16, 2020 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, successfully hosted the first session of its virtual investor mini-series themed "Delivering on the Promise of Synthetic Biology."

This first session entitled Science and Technology, Sustainable Solutions for a Healthier Planet was conducted via live webcast and teleconference yesterday, Tuesday, December 15, 2020 at 1:00pm ET (10:00 am PT). The session included a business update, a technology presentation and Q&A.

The webinar was well-attended with nearly 300 people participating. Speaking on behalf of Amyris during the event were John Melo, President and Chief Executive Officer; Han Kieftenbeld, Chief Financial Officer, and; Sunil Chandran, Senior Vice President, Research and Development.

Mr. Melo provided an update on strategic transactions in the pipeline, a review of the company's portfolio and color commentary regarding the "road ahead" for Amyris. Dr. Chandran followed with an in-depth overview of the power of Amyris' technology platform, its proprietary Lab-to-Market operating system using Genotype Specification Language, and the ability to use machine-learning to design, scale and commercialize molecules at an accelerated rate. The session concluded with an interactive Q&A session.

Presentation materials, a full transcript and a replay of the first virtual investor mini-series are available in the investor relations section of Amyris's website at http://investors.amyris.com.

Amyris plans to hold its second session of the investor mini-series that focuses on its Consumer portfolio during the first quarter of 2021, followed by a third session that highlights its Ingredients portfolio. Advance notice of the dates and times of those sessions will be provided.

About Amyris
Amyris (Nasdaq: AMRS) is a science and technology leader in the research, development and production of sustainable ingredients for the Clean Health & Beauty and Flavors & Fragrances markets. Amyris uses an impressive array of exclusive technologies, including state-of-the-art machine learning, robotics and artificial intelligence. Our ingredients are included in over 3,000 products from the world's top brands, reaching more than 200 million consumers. Amyris is proud to own three consumer brands - all built around its No Compromise® promise of clean ingredients: Biossance™ clean beauty skincare, Pipette™ clean baby skincare and Purecane™, a zero-calorie sweetener naturally derived from sugarcane. For more information, please visit www.amyris.com.

Amyris, the Amyris logo, No Compromise, Biossance, Pipette, and Purecane are trademarks or registered trademarks of Amyris, Inc. in the U.S. and/or other countries.

SOURCES Amyris, Inc.

View original content to download multimedia:http://www.prnewswire.com/news-releases/amyris-hosts-successful-first-session-of-its-virtual-investor-mini-series-301194021.html

SOURCE Amyris, Inc.

FAQ

What was the theme of Amyris's first virtual investor mini-series?

The theme was 'Delivering on the Promise of Synthetic Biology.'

When did Amyris hold its first investor mini-series session?

The session took place on December 15, 2020.

Who presented at the Amyris investor mini-series?

Presenters included CEO John Melo and SVP Sunil Chandran.

What topics were covered in the Amyris investor mini-series?

Topics included a business update, technology presentation, and Q&A.

What future sessions does Amyris plan for its investor mini-series?

Amyris plans to focus on its Consumer and Ingredients portfolios in future sessions.